Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 1/20 | 0.39 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3434620 | 0.81 | LMNA (0.35) | KCNN4KCNA3POLB | |
| SCHEMBL2259159 | 0.79 | POLB (0.35) | KCNN4KCNA3POLB | |
| SCHEMBL1822454 | 0.78 | KCNN4 (0.33) | KCNN4KCNA3 | |
| SCHEMBL1829650 | 0.77 | KCNN4 (0.42) | KCNN4KCNA3 | |
| SCHEMBL2259111 | 0.77 | POLB (0.38) | KCNN4KCNA3POLB | |
| SCHEMBL2260969 | 0.70 | KCNN4 (0.34) | KCNN4KCNA3POLB | |
| SCHEMBL7219595 | 0.66 | KCNN4 (0.51) | KCNN4KCNA3POLB | |
| SCHEMBL1813640 | 0.65 | NR1H2 (0.43) | POLBKIF11 | |
| SCHEMBL2392374 | 0.65 | KCNN4 (0.69) | KCNN4KCNA3 | |
| SCHEMBL23995584 | 0.65 | KCNN4 (0.68) | KCNN4KCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201603-A1 | Novel Acylaminobenzamide Derivatives | BAYER CROPSCIENCE AG (DE) | 2011-08-18 | — | — | US | disclosed |
| EP-2318358-A2 | ACYLAMINOBENZAMIDE DERIVATIVES | Bayer CropScience AG (DE) | 2011-05-11 | — | — | EP | disclosed |
| WO-2010015355-A2 | NOVEL ACYLAMINOBENZAMIDE DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201603-A1 | Novel Acylaminobenzamide Derivatives | KCNB1, KCNA5, KCNA7 | KCNN4 430/4885KCNA3 6/4885POLB 1730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.